COVID-19 Pneumonia Followed by Anti-signal Recognition Particle Antibody-positive Fibrosing Interstitial Lung Disease

Tomoya Tateishi; Sho Shimada; Takashi Yamana; Yuki Iijima; Rie Sakakibara; Takahiro Mitsumura; Sho Shibata; Takayuki Honda; Tsuyoshi Shirai; Tsukasa Okamoto; Meiyo Tamaoka; Tsuneo Sasai; Yasunari Miyazaki

doi:10.2169/internalmedicine.8877-21

CASE REPORTS

COVID-19 Pneumonia Followed by Anti-signal Recognition Particle Antibody-positive Fibrosing Interstitial Lung Disease

Tomoya Tateishi, Sho Shimada, Takashi Yamana, Yuki Iijima, Rie Sakakibara, Takahiro Mitsumura, Sho Shibata, Takayuki Honda, Tsuyoshi Shirai, Tsukasa Okamoto, Meiyo Tamaoka, Tsuneo Sasai, Yasunari Miyazaki

Author information

Tomoya Tateishi
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Department of Respiratory Physiology and Sleep Medicine, Tokyo Medical and Dental University, Japan
Sho Shimada
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Takashi Yamana
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Yuki Iijima
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Rie Sakakibara
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Takahiro Mitsumura
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Sho Shibata
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Takayuki Honda
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Tsuyoshi Shirai
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Tsukasa Okamoto
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Department of Pulmonary Immunotherapeutics, Tokyo Medical and Dental University, Japan
Meiyo Tamaoka
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Department of Respiratory Physiology and Sleep Medicine, Tokyo Medical and Dental University, Japan
Tsuneo Sasai
Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Japan
Yasunari Miyazaki
Department of Respiratory Medicine, Tokyo Medical and Dental University, Japan
Department of Respiratory Physiology and Sleep Medicine, Tokyo Medical and Dental University, Japan
Department of Pulmonary Immunotherapeutics, Tokyo Medical and Dental University, Japan

Keywords: COVID-19, pulmonary fibrosis, interstitial lung disease, anti-SRP antibody

JOURNAL OPEN ACCESS

2023 Volume 62 Issue 9 Pages 1323-1328

DOI https://doi.org/10.2169/internalmedicine.8877-21

Browse “Advance online publication” version

Details

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is frequently accompanied by various sequelae. Interstitial lung diseases (ILDs) are observed in COVID-19 pneumonia patients after recovery, probably due to persistent inflammation in the lungs. We herein report a case of ILD with anti-signal recognition particle antibodies following severe COVID-19 pneumonia. The patient was diagnosed with ILD three months after COVID-19 pneumonia. Although the exact mechanism is unknown, the autoantibody-induced immune response might have been the pulmonary fibrosis trigger in this patient.

Corresponding author

Register with J-STAGE for free!